Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

ABSTRACT:

Objective

There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon-β (IFNβ) therapy, we sought to validate the finding using samples from a large clinical trial.

Methods

The validation cohort included 54 good responders (GR) and 64 poor responders (PR) selected from 762 subjects with RRMS from the IM IFNβ-1a dose comparison study (Avonex study C94-805). Subjects were classified as GR and PR based on the number of relapses, Expanded Disability Status Scale score, and new and enlarging T2 lesions on MRI. Serum sa

SUBMITTER: Bushnell SE 

PROVIDER: S-EPMC3413762 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature